Initial data from the upcoming ASCO annual meeting (American Society of Clinical Oncology annual meeting) dropped last night when abstracts were released at 5:00 PM ET. The biggest loser so far: Puma Biotech (PBYI), which is down 15% into Thursday morning with the latest update from the phase 3 EXTENET trial.
Remember, these are just the initial abstracts. Full datasets and late-breaking abstracts won’t be available until the meeting (May 29 to June 2).
In April we suggested a handful of smid-cap names to have on the watchlist into ASCO. Of these, Oncothyreon (ONTY) looks like it may be the ASCO sleeper play this year among small/mid-cap oncology companies.
Already a Premium user? Sign In
